Literature DB >> 20444885

Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation.

A Young Kim1, Yun Sok Lee, Kang Ho Kim, Jae Ho Lee, Hee Kyu Lee, Su-Hwa Jang, Seong-Eun Kim, Gha Young Lee, Joo-Won Lee, Sung-Ae Jung, Hee Yong Chung, Sunjoo Jeong, Jae Bum Kim.   

Abstract

In obesity, dysregulation of adipocytokines is involved in several pathological conditions including diabetes and certain cancers. As a member of the adipocytokines, adiponectin plays crucial roles in whole-body energy homeostasis. Recently, it has been reported that the level of plasma adiponectin is reduced in several types of cancer patients. However, it is largely unknown whether and how adiponectin affects colon cancer cell growth. Here, we show that adiponectin suppresses the proliferation of colon cancer cells including HCT116, HT29, and LoVo. In colon cancer cells, adiponectin attenuated cell cycle progression at the G(1)/S boundary and concurrently increased expression of cyclin-dependent kinase inhibitors such as p21 and p27. Adiponectin stimulated AMP-activated protein kinase (AMPK) phosphorylation whereas inhibition of AMPK activity blunted the effect of adiponectin on the proliferation of colon cancer cells. Furthermore, knockdown of adiponectin receptors such as AdipoR1 and AdipoR2 relieved the suppressive effect of adiponectin on the growth of colon cancer cells. In addition, adiponectin repressed the expression of sterol regulatory element binding protein-1c, which is a key lipogenic transcription factor associated with colon cancers. These results suggest that adiponectin could inhibit the growth of colon cancer cells through stimulating AMPK activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444885      PMCID: PMC5417469          DOI: 10.1210/me.2009-0498

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  62 in total

1.  Serum adiponectin is not associated with risk of colorectal cancer.

Authors:  Annekatrin Lukanova; Stefan Söderberg; Rudolf Kaaks; Egil Jellum; Pär Stattin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-02       Impact factor: 4.254

2.  Liver AMP-activated protein kinase and acetyl-CoA carboxylase during and after exercise.

Authors:  C L Carlson; W W Winder
Journal:  J Appl Physiol (1985)       Date:  1999-02

3.  Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece.

Authors:  Eleni Petridou; Christos Mantzoros; Nick Dessypris; Panagiotis Koukoulomatis; Carol Addy; Zannis Voulgaris; George Chrousos; Dimitrios Trichopoulos
Journal:  J Clin Endocrinol Metab       Date:  2003-03       Impact factor: 5.958

4.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

5.  Prostate cancer and adiponectin.

Authors:  Serdar Goktas; Mahmut Ilker Yilmaz; Kayser Caglar; Alper Sonmez; Selim Kilic; Selahattin Bedir
Journal:  Urology       Date:  2005-06       Impact factor: 2.649

6.  Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell.

Authors:  Jee Hyun Kang; Yoon Young Lee; Byung Yeon Yu; Beom-Seok Yang; Kyung-Hwan Cho; Do Kyoung Yoon; Yong Kyun Roh
Journal:  Arch Pharm Res       Date:  2005-11       Impact factor: 4.946

7.  Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway.

Authors:  Michiko Sugiyama; Hirokazu Takahashi; Kunihiro Hosono; Hiroki Endo; Shingo Kato; Kyoko Yoneda; Yuichi Nozaki; Koji Fujita; Masato Yoneda; Koichiro Wada; Hitoshi Nakagama; Atsushi Nakajima
Journal:  Int J Oncol       Date:  2009-02       Impact factor: 5.650

8.  Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients.

Authors:  Anna Kumor; Piotr Daniel; Mirosława Pietruczuk; Ewa Małecka-Panas
Journal:  Int J Colorectal Dis       Date:  2008-11-01       Impact factor: 2.571

9.  Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia.

Authors:  Elife Erarslan; Cansel Turkay; Aslý Koktener; Cemile Koca; Burak Uz; Nuket Bavbek
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

10.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  96 in total

Review 1.  Adiponectin as a Potential Therapeutic Target for Prostate Cancer.

Authors:  Hanuma Kumar Karnati; Manas Kumar Panigrahi; Yazhou Li; David Tweedie; Nigel H Greig
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 2.  Obesity, energy balance, and cancer: new opportunities for prevention.

Authors:  Stephen D Hursting; John Digiovanni; Andrew J Dannenberg; Maria Azrad; Derek Leroith; Wendy Demark-Wahnefried; Madhuri Kakarala; Angela Brodie; Nathan A Berger
Journal:  Cancer Prev Res (Phila)       Date:  2012-10-03

3.  Risk of Colorectal Neoplasia According to Fatty Liver Severity and Presence of Gall Bladder Polyps.

Authors:  Taeyoung Lee; Kyung Eun Yun; Yoosoo Chang; Seungho Ryu; Dong Il Park; Kyuyong Choi; Yoon Suk Jung
Journal:  Dig Dis Sci       Date:  2015-09-18       Impact factor: 3.199

4.  Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma.

Authors:  Rong-Rong Song; Xiao-Lin Gu
Journal:  Tumour Biol       Date:  2014-12-11

Review 5.  Insights into the Link Between Obesity and Cancer.

Authors:  Sarah E Ackerman; Olivia A Blackburn; François Marchildon; Paul Cohen
Journal:  Curr Obes Rep       Date:  2017-06

6.  Underactivation of the adiponectin-adiponectin receptor 1 axis in clear cell renal cell carcinoma: implications for progression.

Authors:  Nir Kleinmann; Wilhelmina C M Duivenvoorden; Sarah N Hopmans; Laura K Beatty; Shengjun Qiao; Daniel Gallino; Sarka Lhotak; Dean Daya; Athanasios Paschos; Richard C Austin; Jehonathan H Pinthus
Journal:  Clin Exp Metastasis       Date:  2013-10-05       Impact factor: 5.150

Review 7.  Obesity and cancer--mechanisms underlying tumour progression and recurrence.

Authors:  Jiyoung Park; Thomas S Morley; Min Kim; Deborah J Clegg; Philipp E Scherer
Journal:  Nat Rev Endocrinol       Date:  2014-06-17       Impact factor: 43.330

Review 8.  Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression.

Authors:  Ayca Gucalp; Neil M Iyengar; Clifford A Hudis; Andrew J Dannenberg
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

9.  Mucus and adiponectin deficiency: role in chronic inflammation-induced colon cancer.

Authors:  Arpit Saxena; Manjeshwar Shrinath Baliga; Venkatesh Ponemone; Kamaljeet Kaur; Bianca Larsen; Emma Fletcher; Jennifer Greene; Raja Fayad
Journal:  Int J Colorectal Dis       Date:  2013-03-09       Impact factor: 2.571

Review 10.  Mechanisms linking obesity and cancer.

Authors:  Sharon M Louie; Lindsay S Roberts; Daniel K Nomura
Journal:  Biochim Biophys Acta       Date:  2013-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.